Blueprint Medicines
Cambridge, US · 4 known investors
Find your way into Blueprint Medicines
759 people in our graph share verified history with the Blueprint Medicines team — schools, employers, funds. One of them is your warm intro.
Dan Lynchunlockedknows Christoph Lengauer · together at Blueprint Medicines (overlapped)
knows the team · via The Johns Hopkins University
×5knows the team · via Third Rock Ventures
×2knows the team · via Cancerresearchuk
×2knows the team · via Heidelberg University
knows the team · via Creative Destruction Lab
Blueprint Medicines is a biopharmaceutical company that discovers and develops targeted medicines for patients with diseases such as gastrointestinal stromal tumor and other conditions driven by genetic changes. It markets approved therapies internationally and runs patient access programs across multiple countries.
Founders & leadership
NL
Nick LydonCo-founder
CS
Christoph S. Lengauerin𝕏Co-founder · Executive Vice President2016–2021Christoph Lengauer is an Executive Officer at Blueprint Medicines, a biopharmaceutical company developing targeted therapies for genetically-driven diseases including gastrointestinal stromal tumor.
CB
Christine BelloninVP, Legal Affairs2011–2016
KK
Kyle KuvalankainChief Business Officer2013–2015
Board
AB
Alexis BorisyBoard director
DL
Daniel LynchBoard director
SK
Stephen KnightBoard director
TS
Thilo SchroederBoard director
DS
David SchenkeinBoard director
Investors · 4
Funding
SEC filings, press & company announcements$73.2M disclosed across 2 of 3 rounds · 2014–2026
- Undisclosed amountSeries CMar 2026Source ↗
▶$50MraisedNov 2014 · 29 investors · BiotechnologyRule 506(b)
▶$50MraisedNov 2014 · 29 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alexis BorisyDirector
- Nicholas LydonDirector
- Jeffrey W. AlbersExecutive Officer, Director
- Kyle KuvalankaExecutive Officer
- Stephen KnightDirector
- Thilo SchroederDirector
- Christoph S. LengauerExecutive Officer
- David SchenkeinDirector
- Daniel LynchDirector
- Christine BellonExecutive Officer
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Nov 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$23.2MraisedJan 2014 · 10 investors · BiotechnologyRule 506(b)
▶$23.2MraisedJan 2014 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alexis BorisyExecutive Officer, Director
- Daniel LynchDirector
- Nick LydonDirector
- David SchenkeinDirector
- Stephen KnightDirector
- Thilo SchroederDirector
- Christoph S. LengauerExecutive Officer
- Christine BellonExecutive Officer
- Kyle KuvalankaExecutive Officer
- Offering amount
- $25.1M
- Amount sold
- $23.2M
- First sale
- Jan 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Blueprint Medicines went on to found or lead other companies.
In the news
Frequently asked questions
- What does Blueprint Medicines do?
- Blueprint Medicines is a biopharmaceutical company that discovers and develops targeted medicines for patients with diseases such as gastrointestinal stromal tumor and other conditions driven by genetic changes. It markets approved therapies internationally and runs patient access programs across multiple countries.
- Who founded Blueprint Medicines?
- Blueprint Medicines was founded by Nick Lydon, Christoph S. Lengauer.
- Who are Blueprint Medicines's investors?
- Blueprint Medicines's investors include F-Prime Capital, Foresite Capital, Nextech Invest, RA Capital.
- How much funding has Blueprint Medicines raised?
- Blueprint Medicines has disclosed $73.2M raised across 2 of its 3 known rounds.
- Where is Blueprint Medicines headquartered?
- Blueprint Medicines is headquartered in Cambridge, US.